EpicBioCMYK300dpi.png
Epic Bio Presents New Data Highlighting Potential of EPI-321 for FSHD and Epigenetic Editing Platform Leadership at ASGCT Annual Meeting
23 avr. 2024 09h00 HE | Epic Bio
SOUTH SAN FRANCISCO, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Epic Bio, a leading epigenetic editing company that plans to have its FSHD program enter the clinic this year, today shared details of...
EpicBioCMYK300dpi.png
Epic Bio Announces Robust Slate of Presentations at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting
09 avr. 2024 09h00 HE | Epic Bio
SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Epic Bio, a leading epigenetic editing company that plans to have its FSHD program enter the clinic this year, today announced the...
EpicBioCMYK300dpi.png
Epic Bio to Participate in a Fireside Chat at the Cantor Virtual Muscular Dystrophy Symposium
01 avr. 2024 16h00 HE | Epic Bio
SOUTH SAN FRANCISCO, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Epic Bio, a leading epigenetic editing company that plans to dose its first patients later this year, today announced that Amber...
EpicBioCMYK300dpi.png
Epic Bio to Present at the Upcoming CRISPR2.0 Conference
21 nov. 2023 12h00 HE | Epic Bio
SOUTH SAN FRANCISCO, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today...
EpicBioCMYK300dpi.png
FDA Grants Orphan Drug Designation to EPI-321, Epic Bio's Novel Genetic Medicine Candidate for Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)
16 nov. 2023 06h00 HE | Epic Bio
- Potential one-time therapy for the treatment of FSHD includes a novel non-cutting dCas protein delivered via a single AAV - - EPI-321 is the only therapy designed to target the epigenetic root...
EpicBioCMYK300dpi.png
Epic Bio to Participate in Upcoming Investor Conference
07 nov. 2023 06h00 HE | Epic Bio
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today...
EpicBioCMYK300dpi.png
Epic Bio Reports New Data on Hypercompact Cas Proteins Optimized for Broad Therapeutic Applicability
26 oct. 2023 11h09 HE | Epic Bio
Epic Bio presented new details on an in-house engineered suite of Cas molecules derived from CasMINI, the smallest Cas known to work in human cells.
EpicBioCMYK300dpi.png
Epic Bio to Present at the Upcoming Annual European Society of Gene and Cell Therapy
19 oct. 2023 06h00 HE | Epic Bio
SOUTH SAN FRANCISCO, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today...
EpicBioCMYK300dpi.png
Epic Bio Announces the Appointment of Weston Miller, M.D., as Chief Medical Officer
17 oct. 2023 06h00 HE | Epic Bio
SOUTH SAN FRANCISCO, Calif., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today...
EpicBioCMYK300dpi.png
Epic Bio to Present at the Upcoming BMO Life Sciences Private Company Showcase
05 oct. 2023 09h00 HE | Epic Bio
SOUTH SAN FRANCISCO, Calif., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today...